April 26, 2024
Market Now
Daewha Pharma’s cancer drug candidate IND granted by USFDA
[DISCLOSURE] Daehwa Pharmaceutical (067080) announced on Sept. 21 that its investigational new drug application for Liporaxel has been granted by the USFDA to advance to the second phase of clinical trials for breast cancer.
By Hwang You-mee (glamazon@heraldcorp.com)
By Hwang You-mee (glamazon@heraldcorp.com)
![[KH Explains] Korean shipbuilding stocks rally: Real growth or bubble?](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=151&simg=/content/image/2024/04/25/20240425050656_0.jpg)
![[Hello India] Hyundai Motor vows to boost 'clean mobility' in India](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=151&simg=/content/image/2024/04/25/20240425050672_0.jpg)
